
Opinion|Videos|April 14, 2025
Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
Panelists discuss how response rates, progression-free survival, and overall survival data presented at the European Lung Cancer Conference (ELCC 2025) demonstrate meaningful clinical outcomes while highlighting important safety considerations for patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5
































